Clinical characteristics, treatment patterns, and costs among hospitalised patients with cardiomyopathy: a multicentre retrospective tertiary-hospital study across China.

Authors

Leqi Wang, Chunping Wang, Yingying Zheng, Peijin Li, Kai Huang, Xuejun Jiang, Haonan Li, Zeqi Zheng, Wei Li, Fang Qin, Lian Wang, Chongyou Lee, Yanli Long, Junnan Tang, Lianjun Xu, Carolyn S P Lam, Sheng Han, Lei Song

Published in

The Lancet regional health. Western Pacific. Volume 73. Pages 101943. Epub Aug 08, 2026.

Abstract

Characterising treatment patterns and costs is essential for understanding healthcare utilisation and informing cost management. We aimed to assess these aspects among hospitalised patients with cardiomyopathy.
We conducted a multicentre study at 11 tertiary hospitals across China, systematically extracting electronic medical records from 2017 to 2022. Factors associated with medical costs were analysed using generalised linear regression with cluster-robust standard errors.
Among 15,764 medical records of adult inpatients with cardiomyopathy, medical therapy alone (81.5%; 12,853/15,764) was the most common treatment pattern. The mean direct medical cost per hospitalisation for all admissions was $6294 ($11,564) and the median cost was $2152 (IQR $1248, $4931), with variation across cardiomyopathy subtypes. Admissions to the national centre (Exp(β) 1.529 [95% confidence interval 1.242-1.882]), New York Heart Association functional class III/IV (Exp(β) 1.371 [1.169-1.608]), and combination therapies (vs. medical therapy alone: medical and interventional Exp(β) 6.685 [5.098-8.766]; medical and surgical 7.537 [6.213-9.143]; all three 10.718 [7.579-15.157]) were associated with higher costs, whereas insurance coverage (Exp(β) 0.773 [0.642-0.932]) was associated with lower costs.
This study provides evidence on inpatient medical costs and their associated factors, serving as a reference for understanding the real-world cost profile and informing cost management of cardiomyopathy in tertiary healthcare settings.
The Noncommunicable Chronic Diseases-National Science and Technology Major Project, the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences, the National High Level Hospital Clinical Research Funding, and the Science and Technology Department of Heilongjiang Province.

PMID:
42604170
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.